{"schema_version":"secwatch.filing_event.v1","accession":"0001793229-23-000119","form_type":"8-K","ticker":"CTEV","cik":"0001793229","company_name":"Claritev Corp","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.480384+00:00","generated_at":"2026-06-08T16:52:49.713743+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MultiPlan Q3 2023 revenue $242.8M, net loss $24.1M; FY guidance tightened","bullets":["Q3 2023 revenue $242.8M (-3.1% YoY); net loss $24.1M vs net income $19.7M in Q3 2022.","Adjusted EBITDA $152.3M; Free Cash Flow $49.7M, down from $88.2M prior year.","Repurchased $46.1M face value of 5.75% Senior Unsecured Notes in open market during Q3.","FY 2023 guidance updated: revenue $960-970M (from $950-980M), Adjusted EBITDA $615-625M (from $615-635M).","Identified ~$5.8B in potential medical cost savings in Q3, up 7% YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001793229-23-000119","json":"https://secwatch.observer/filing/0001793229-23-000119.json","markdown":"https://secwatch.observer/filing/0001793229-23-000119.md","text":"https://secwatch.observer/filing/0001793229-23-000119.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1793229/000179322923000119/0001793229-23-000119-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1793229/000179322923000119/mpln-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T16:52:49.713743+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d32b5a5fb7e2ecef17010bfaf3f192f5ccab32b1","claim":"Claritev Corp reported Full Year 2023 results: revenue $960 million to $970 million. Guidance reaffirmed.","evidence_excerpt":"as detailed in the table below. All other guidance items remain unchanged. Financial Metric Prior FY 2023 Guidance Revised FY 2023 Guidance Revenues $950 million to $980 million $960 million to $970 million Adjusted EBITDA 1 $615 million to $635 million $615 million to $625 million Interest expense $325 million to $335 million Cash flow from operations 2 $160 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1793229/000179322923000119/0001793229-23-000119-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year 2023"},{"label":"Revenue","value":"$960 million to $970 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"f5aff79803522e4e5ec498668f18d425eca12c2e","claim":"Claritev Corp reported the third quarter ended September 30, 2023 results: revenue $242.8 million, net income Net loss of $24.1 million. Guidance reaffirmed.","evidence_excerpt":"Act, regardless of any general incorporation language in such filings. --- EX-99.1 (EX-99.1) --- RELEASE MultiPlan Reports Third Quarter 2023 Results – Q3 2023 Revenues of $242.8 million, Net Loss of $24.1 million, and Adjusted EBITDA of $152.3 million – Identified potential medical cost savings of approximately $5.8 billion in Q3 2023, up 2% from Q2 2023 and up","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1793229/000179322923000119/0001793229-23-000119-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$242.8 million"},{"label":"Net income","value":"Net loss of $24.1 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}